2024
Cost‐Effectiveness of Community‐Based Diet and Exercise for Patients with Knee Osteoarthritis and Obesity or Overweight
Kopp P, Yang C, Yang H, Katz J, Paltiel A, Hunter D, Callahan L, Mihalko S, Newman J, DeVita P, Loeser R, Miller G, Messier S, Losina E. Cost‐Effectiveness of Community‐Based Diet and Exercise for Patients with Knee Osteoarthritis and Obesity or Overweight. Arthritis Care & Research 2024, 76: 1018-1027. PMID: 38450873, DOI: 10.1002/acr.25323.Peer-Reviewed Original ResearchBody mass indexUsual careQuality-adjusted life yearsHealth educationIncremental cost-effectiveness ratioKnee osteoarthritisKnee OAGroup-based health educationWestern Ontario and McMaster Universities Osteoarthritis Index pain scoreLifetime costsOA careE programCost-effectiveIncremental cost-effectivenessFunctional limitationsIncreased lifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioLife yearsMass indexPain reductionSocietal perspectiveCohort characteristicsKneeExercise
2019
Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDiet
2017
Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa
Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infectious Diseases 2017, 4: ofx081. PMID: 28680903, PMCID: PMC5490502, DOI: 10.1093/ofid/ofx081.Peer-Reviewed Original ResearchHIV cure strategiesCure strategiesHuman immunodeficiency virus (HIV) eradicationLifetime antiretroviral therapySustained viral eradicationElimination of HIVStandard of careLifetime costsAntiretroviral therapyViral eradicationHIV cureFatal toxicitySingle interventionVirus eradicationLife expectancyCureLower lifetime costsSingle caseSurvival
2016
Cost‐Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis
Smith SR, Katz JN, Collins JE, Solomon DH, Jordan JM, Suter LG, Yelin EH, Paltiel AD, Losina E. Cost‐Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. Arthritis Care & Research 2016, 69: 234-242. PMID: 27111538, PMCID: PMC5378156, DOI: 10.1002/acr.22916.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsOA patientsTKA outcomesKnee OA patientsKnee osteoarthritis treatmentInfluence of opioidsOsteoarthritis Policy ModelCost-effectiveness ratioConservative treatmentPain reductionPain reliefPersistent painKnee osteoarthritisMean ageTKA utilizationTreatment optionsOsteoarthritis treatmentLife yearsOxycodoneTramadolTKALifetime costsOpioidsOutcomes
2015
Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty
Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, Klara K, Suter LG, Solomon DH, Burbine SA, Walensky RP, Katz JN. Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty. Arthritis Care & Research 2015, 67: 203-215. PMID: 25048053, PMCID: PMC4422214, DOI: 10.1002/acr.22412.Peer-Reviewed Original ResearchConceptsTotal knee arthroplastyDirect medical costsOA patientsKnee osteoarthritisMedical costsKnee arthroplastyTKA utilizationEligibility criteriaEffective nonoperative therapiesKellgren/LawrenceKnee osteoarthritis managementKnee OA patientsSymptomatic knee osteoarthritisMulticenter Osteoarthritis StudyLifetime costsUtilization Project dataOsteoarthritis Policy ModelLifetime direct medical costsLifetime medical costsHealth care costsMedicare reimbursement schedulesTotal lifetime costsNonoperative therapySymptomatic osteoarthritisOsteoarthritis management
2014
The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis
Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, Losina E, Bassett IV, Pei PP, Paltiel AD, Resch S, Freedberg KA, Peter T, Walensky RP. The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. PLOS Medicine 2014, 11: e1001725. PMID: 25225800, PMCID: PMC4165752, DOI: 10.1371/journal.pmed.1001725.Peer-Reviewed Original ResearchConceptsCare CD4 testIncremental cost-effectiveness ratioCare CD4 testingPOC CD4CD4 testCD4 testingResource-limited settingsHIV diagnosisHIV testingClinical outcomesAntiretroviral therapy (ART) eligibilityPerson lifetime costsLife expectancyLifetime costsCost-effectiveness ratioResource limited settingsCost-effectiveness analysisSensitivity/specificityImmunological stagingLow sensitivity/specificityCost-effective thresholdLaboratory-based testsSurvivalEditors' SummaryOutcomes
2012
Newer drugs and earlier treatment
Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment. AIDS 2012, 26: 45-56. PMID: 22008655, PMCID: PMC3237010, DOI: 10.1097/qad.0b013e32834dce6e.Peer-Reviewed Original ResearchConceptsCD4 cell countAntiretroviral therapyHIV RNACD4 cellsHIV diseaseCells/Life expectancyCell countMean CD4 cell countMean age 38 yearsAge 38 yearsMedical resource utilizationLifetime costsUndiscounted life expectancyCost of careAIDS Complications (CEPAC) modelART initiationHIV CostRegimen costsAntiretroviral drugsART costsEarly treatmentCopies/High-income countriesEfficacious drugs
2009
Cost-effectiveness of Total Knee Arthroplasty in the United States: Patient Risk and Hospital Volume
Losina E, Walensky RP, Kessler CL, Emrani PS, Reichmann WM, Wright EA, Holt HL, Solomon DH, Yelin E, Paltiel AD, Katz JN. Cost-effectiveness of Total Knee Arthroplasty in the United States: Patient Risk and Hospital Volume. JAMA Internal Medicine 2009, 169: 1113-1121. PMID: 19546411, PMCID: PMC2731300, DOI: 10.1001/archinternmed.2009.136.Peer-Reviewed Original Research
2002
State AIDS Drug Assistance Programs
Johri M, Paltiel A, Goldie S, Freedberg K. State AIDS Drug Assistance Programs. Medical Care 2002, 40: 429-441. PMID: 11961477, DOI: 10.1097/00005650-200205000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsCD4 Lymphocyte CountCost of IllnessCost-Benefit AnalysisDirect Service CostsDisease ProgressionEfficiency, OrganizationalEligibility DeterminationHealth Services AccessibilityHumansInsurance CoverageInsurance, Pharmaceutical ServicesLife ExpectancyMedical AssistanceModels, EconometricOrganizational InnovationQuality-Adjusted Life YearsState Health PlansUnited StatesConceptsQuality-adjusted life yearsLifetime direct medical costsLife yearsDirect medical costsDrug Assistance ProgramsAssistance programsState-transition simulation modelQuality-adjusted life expectancyADAP programEconomic performanceLife expectancyMedical costsCost-effective useLifetime costsCost dataServices Utilization SurveyState policyAIDS CostState AIDSCoverage variesComprehensive policyUtilization SurveyPolicyCare resourcesPessimistic assumptionsLifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy
Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. Antiviral Therapy 2002, 7: 257-266. PMID: 12553480, DOI: 10.1177/135965350200700405.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyHIV infectionCD4 strataAntiretroviral therapyHIV careHIV diseaseLifetime costsHighly Active Antiretroviral TherapyHigher CD4 strataHIV Clinical CohortLowest CD4 stratumCD4 cell countEra of HAARTBurden of diseaseStage of illnessCost of careHealth policy plannersHealth care costsClinical managementSpecific AIDSClinical cohortMean costFrench patientsCare costsCell count